NewLimit, the longevity biotech startup co-founded by Coinbase CEO Brian Armstrong, closed a $435 million Series C funding round on June 2 to advance its first age-reprogramming medicine into human clinical trials. The round, led by Founders Fund, values the company at $3.1 billion—more than triple its prior valuation—and marks Armstrong's largest non-crypto investment commitment. The funding will support NewLimit's epigenetic reprogramming technology, which aims to restore youthful cellular function without altering DNA sequences, with a planned human trial launch next year. The longevity biotech sector has attracted significant venture capital in 2026, though few startups have reached clinical-stage readiness.
NewLimit Raises $435 Million at $3.1 Billion Valuation
NewLimit announced the Series C round on June 2, naming Thrive Capital, Greenoaks and Quiet Capital as new investors. Existing backers Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures and Human Capital also participated. The Wall Street Journal reported the $3.1 billion valuation, which represents more than three times the company's valuation from the previous year.
Founded in 2021, NewLimit has compressed its timeline for advancing an aging medicine to human trials. The company initially estimated that reaching human trials would take more than a decade but credited recent scientific breakthroughs with accelerating the timeline significantly.
Epigenetic Reprogramming Technology Targets Liver Cells
NewLimit focuses on epigenetic reprogramming, a technique that aims to restore youthful function in aging cells without altering their DNA sequence. Its lead program targets liver cells, where early research showed old human liver tissue regaining markers of younger function in laboratory settings.
"Following breakthrough results, we're bringing longevity medicine to human trials," NewLimit posted on X. "Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it."
The company is led by co-founder Jacob Kimmel, a computational biologist who serves as CEO and president. Blake Byers, a former GV partner and bioengineer, is the third co-founder.
Brian Armstrong Co-Founds Longevity Biotech Startup
The $435 million biotech raise represents Armstrong's largest non-crypto commitment. Armstrong has steered Coinbase toward AI integration, with the exchange reportedly cutting account restriction resolution times by 90% using automated tools. Stablecoins, tokenization and automation have featured prominently in his recent public remarks about the future of financial infrastructure.
The raise signals a pattern among crypto executives channeling wealth into adjacent technology sectors.
Longevity Sector Attracts Venture Capital in 2026
The longevity sector has attracted significant venture capital in 2026, though few startups have reached clinical-stage readiness. NewLimit's round places it among the best-funded private companies in the space, alongside Altos Labs and Retro Biosciences. The participation of Eli Lilly Ventures adds pharmaceutical industry validation to a field still largely driven by tech-sector capital.
NewLimit Plans Human Trial Filing Next Year
NewLimit plans to file for its first human trial next year and expand its research pipeline across liver, immune, metabolic and vascular programs. The company has no approved product and must now demonstrate that cell-level results translate into a safe, effective human therapy.
FAQ
What did NewLimit announce on June 2?
NewLimit announced the close of a $435 million Series C funding round led by Founders Fund on June 2. The round values the company at $3.1 billion, more than triple its prior valuation, and will support advancing its first age-reprogramming medicine into human clinical trials.
What technology does NewLimit focus on?
NewLimit focuses on epigenetic reprogramming, a technique that aims to restore youthful function in aging cells without altering their DNA sequence. Its lead program targets liver cells, where early research showed old human liver tissue regaining markers of younger function in laboratory settings.
When does NewLimit plan to begin human trials?
NewLimit plans to file for its first human trial next year. The company initially estimated that advancing an aging medicine to human trials would take more than a decade but credited recent scientific breakthroughs with compressing that timeline significantly.
